Secondly, long-term inhibition of TLR9 activity not only impedes progression but also reverses the pathophysiological phenomena observed in the lungs and reduces the expression of mRNA of the main proinflammatory interleukin in the pathogenesis of PAH, i.e., IL-6. Here, TLR9 is linked to pulmonary arterial hypertension.